Log In
BCIQ
Print this Print this
 

NI-0501

  Manage Alerts
Collapse Summary General Information
Company Novimmune S.A.
DescriptionHuman mAb against interferon (IFN) gamma
Molecular Target Interferon (IFN) gamma
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II/III
Standard Indication Hematology (unspecified)
Indication DetailsTreat primary hemophagocytic lymphohistiocytosis (HLH); Treat primary hemophagocytic lymphohistiocytosis (HLH) with refractory disease, or with recurrent or progressive disease during conventional therapy
Regulatory Designation U.S. - Breakthrough Therapy (Treat primary hemophagocytic lymphohistiocytosis (HLH) with refractory disease, or with recurrent or progressive disease during conventional therapy);
EU - Orphan Drug (Treat primary hemophagocytic lymphohistiocytosis (HLH));
EU - PRIority MEdicines (PRIME) (Treat primary hemophagocytic lymphohistiocytosis (HLH))
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today